Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Pituitary Neoplasms × farletuzumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 4 Carcinoma, Ovarian Epithelial 2 Pituitary Neoplasms 1 Peritoneal Neoplasms 1 Neoplasms 1 Fallopian Tube Neoplasms 1 Adenocarcinoma of Lung 1

Interventions

pasireotide 4 Cabergoline 3 pegvisomant 1 farletuzumab 1 TBR-760 1 Octreotide 1 90Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01203618 2013-11-04

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Morphotek

Phase 2 Withdrawn

Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡